| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/08/2006 | CA2588465A1 Pharmaceutical composition containing an anti-nucleating agent |
| 06/08/2006 | CA2588454A1 Formulations of substituted benzoxazoles |
| 06/08/2006 | CA2588445A1 Pharmaceutical formulation containing a release rate controlling composition |
| 06/08/2006 | CA2588086A1 Protein delivery system |
| 06/08/2006 | CA2586807A1 Topical nepafenac formulations |
| 06/08/2006 | CA2586488A1 Cosmetic patch for skin treatment |
| 06/08/2006 | CA2586323A1 Aqueous dispersions of a mixture of only slightly water soluble or water insoluble active substances and a single-celled protein material |
| 06/07/2006 | EP1666585A1 Macroencapsulated secretory cells |
| 06/07/2006 | EP1666557A1 Adhesive and thermal material stuck in use produced therewith |
| 06/07/2006 | EP1666518A1 Hyaluronic acid modification products and drug carriers using them |
| 06/07/2006 | EP1666503A1 Polysaccharide pseudo-sponge |
| 06/07/2006 | EP1666130A1 Process for producing a fine emulsion from a coarse emulsion |
| 06/07/2006 | EP1666071A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666070A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666056A1 Cancer vaccine vesicles |
| 06/07/2006 | EP1666054A1 Method for administering insulinotropic peptides |
| 06/07/2006 | EP1666044A1 Male contraceptive formulation comprising norethisterone |
| 06/07/2006 | EP1666043A1 Product containing prostaglandin |
| 06/07/2006 | EP1666039A1 Use of L-alpha-lysophosphatidylcholine inhibitors to prevent inflammation |
| 06/07/2006 | EP1666032A1 Lowly irritative adhesive patch |
| 06/07/2006 | EP1666031A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein |
| 06/07/2006 | EP1666030A1 Improved nicotine lozenge and therapeutic method for smoking cessation |
| 06/07/2006 | EP1666029A1 Pressurised metered dose inhalers (MDI) |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1666026A2 Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
| 06/07/2006 | EP1666025A1 DRUG DELIVERY SYSTEM FOR SUB-TENON’S CAPSULE ADMINISTRATION OF FINE GRAINS |
| 06/07/2006 | EP1666024A1 Preparation for rectal administration |
| 06/07/2006 | EP1666023A2 Improvements in and relating to carrier particles for use in dry powder inhalers |
| 06/07/2006 | EP1666020A1 Compositions for the preparation of carbon dioxide gel for external use and carbon dioxide gels for external use |
| 06/07/2006 | EP1664761A1 Screening method of formulating a pharmaceutical composition by using model compounds |
| 06/07/2006 | EP1664316A1 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 06/07/2006 | EP1664272A2 Targeting endothelium for tissue-specific delivery of agents |
| 06/07/2006 | EP1664044A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 06/07/2006 | EP1663933A2 Improved delivery by labile hydrophobic modification of drugs |
| 06/07/2006 | EP1663397A1 Injectable therapeutic formulations |
| 06/07/2006 | EP1663395A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 06/07/2006 | EP1663384A2 System and apparatus for remote activation of implantable medical devices |
| 06/07/2006 | EP1663381A1 Sonophoresis skin care device |
| 06/07/2006 | EP1663343A2 Application of a therapeutic substance to a tissue location using an expandable medical device |
| 06/07/2006 | EP1663331A1 Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agents |
| 06/07/2006 | EP1663315A2 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 06/07/2006 | EP1663314A2 Pharmaceutical products comprising bisphosphonates |
| 06/07/2006 | EP1663296A1 Liquid human growth hormone formulation containing polyethylene glycol |
| 06/07/2006 | EP1663295A2 Stable formulations of peptides |
| 06/07/2006 | EP1663282A1 Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin |
| 06/07/2006 | EP1663273A1 Powdery composition for use as a laxative |
| 06/07/2006 | EP1663253A2 Formulations and methods of treating inflammatory bowel disease |
| 06/07/2006 | EP1663252A1 Application assembly for medicaments that are to be applied to the skin and packaging that is used as an application assembly |
| 06/07/2006 | EP1663243A1 Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer |
| 06/07/2006 | EP1663229A2 Pharmaceutical combinations of hydrocodone and naltrexone |
| 06/07/2006 | EP1663226A1 Pharmaceutical compositions of moxifloxacin and processes for their preparation |
| 06/07/2006 | EP1663217A1 Solid dispersions comprising tacrolimus |
| 06/07/2006 | EP1663216A1 Modified release compositions comprising tacrolimus |
| 06/07/2006 | EP1663212A1 Solid dosage formulation containing a factor xa inhibitor and method |
| 06/07/2006 | EP1663209A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-ethyl proprionate and salts thereof |
| 06/07/2006 | EP1663191A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 06/07/2006 | EP1663188A2 Treatment of disorders of the nervous system |
| 06/07/2006 | EP1663186A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 06/07/2006 | EP1663183A2 Solid pharmaceutical dosage form |
| 06/07/2006 | EP1663182A1 Rapid dissolution formulation of a calcium receptor-active compound |
| 06/07/2006 | EP1663179A1 Composition and method for controlling drug delivery from silicone adhesive blends |
| 06/07/2006 | EP1663178A1 Films based on poly(ethylene oxide), and drug delivery systems made thereof |
| 06/07/2006 | EP1663177A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 06/07/2006 | EP1663176A1 Medicinal skin adhesives containing essential oils for the treatment of common colds, and method for the production thereof |
| 06/07/2006 | EP1663175A2 Oral drug delivery system |
| 06/07/2006 | EP1663174A1 Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent |
| 06/07/2006 | EP1663173A1 Enteric soft gelatin capsule containing esomeprazole and method of preparation |
| 06/07/2006 | EP1663172A1 Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration |
| 06/07/2006 | EP1663171A2 Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions |
| 06/07/2006 | EP1663170A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/07/2006 | EP1663169A1 Antibiotic product, use and formulation thereof |
| 06/07/2006 | EP1663168A2 Nicotine formulations and use thereof |
| 06/07/2006 | EP1663167A1 Dosage forms with an enterically coated core tablet |
| 06/07/2006 | EP1663166A2 Sustained release dosage forms of ziprasidone |
| 06/07/2006 | EP1663165A2 Improved stearate composition and method of production thereof |
| 06/07/2006 | EP1663164A2 Methods for preparing pharmaceutical compositions |
| 06/07/2006 | EP1663163A2 Particles shaped as platelets |
| 06/07/2006 | EP1663162A2 Orally administrable dosage form for poorly soluble acids and amphoteric active ingredients |
| 06/07/2006 | EP1663161A2 Slow release estradiol-progesterone formulation for contraception and hormone replacement therapy |
| 06/07/2006 | EP1663159A2 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| 06/07/2006 | EP1663158A2 Specific delivery of drugs to the brain |
| 06/07/2006 | EP1663157A2 Stabilized formulations of phosphatidylserine |
| 06/07/2006 | EP1663156A2 Chronotherapeutic dosage forms |
| 06/07/2006 | EP1663155A2 Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
| 06/07/2006 | EP1663154A1 i MAHONIA /i i AQUIFOLIUM /i EXTRACT, EXTRACTION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| 06/07/2006 | EP1663153A1 Combination chemotherapy comprising a liposomal platinum complex |
| 06/07/2006 | EP1663152A2 Process for the production of homogeneous liposomes and lipoplexes |
| 06/07/2006 | EP1663150A2 Novel inhalation powder comprising the cgrp antagonist 1-[ n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine |
| 06/07/2006 | EP1663149A2 Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant |
| 06/07/2006 | EP1663148A2 Penetrating pharmaceutical foam |
| 06/07/2006 | EP1663146A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 06/07/2006 | EP1663145A1 Oros-push-stick for controlled delivery of active agents |
| 06/07/2006 | EP1663144A1 Triamcinolone acetonide and anecortave acetate formulations for injection |
| 06/07/2006 | EP1663143A2 Solid or semi-solid therapeutic formulations |
| 06/07/2006 | EP1663142A2 Compositons and methods for topical administration |
| 06/07/2006 | EP1663141A1 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline |
| 06/07/2006 | EP1663132A1 Anhydrous topical formulation for polyphenols |
| 06/07/2006 | EP1663112A2 Intranasal opioid compositions |
| 06/07/2006 | EP1663111A2 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
| 06/07/2006 | EP1663109A2 Ultrasonic concentration of drug delivery capsules |